End­points Man­u­fac­tur­ing: 5 Ques­tions with Ho­mol­o­gy Med­i­cines

This week, I asked five ques­tions of Tim Kel­ly, the chief tech­nol­o­gy of­fi­cer at Ho­mol­o­gy Med­i­cines. Kel­ly has over two decades of ex­pe­ri­ence in man­u­fac­tur­ing, hav­ing spent time at Sarep­ta and Shire be­fore join­ing Ho­mol­o­gy.

The Bed­ford, MA com­pa­ny is seek­ing to har­ness a nov­el tech­nol­o­gy that us­es AAV vec­tors de­rived from hu­man hematopoi­et­ic stem cells that are de­signed to pre­cise­ly and ef­fi­cient­ly de­liv­er ge­net­ic med­i­cines in­to the hu­man body. Part of Kel­ly’s tenure has in­clud­ed con­struc­tion of the com­pa­ny’s in-house man­u­fac­tur­ing fa­cil­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.